443 related articles for article (PubMed ID: 24732808)
1. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Li Y; Li PK; Roberts MJ; Arend RC; Samant RS; Buchsbaum DJ
Cancer Lett; 2014 Jul; 349(1):8-14. PubMed ID: 24732808
[TBL] [Abstract][Full Text] [Related]
2. [Molecular mechanisms of niclosamide antitumor activity].
Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Pan JX; Ding K; Wang CY
Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
[TBL] [Abstract][Full Text] [Related]
4. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells.
Wang YC; Chao TK; Chang CC; Yo YT; Yu MH; Lai HC
PLoS One; 2013; 8(9):e74538. PubMed ID: 24058587
[TBL] [Abstract][Full Text] [Related]
5. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Ma R; Ma ZG; Gao JL; Tai Y; Li LJ; Zhu HB; Li L; Dong DL; Sun ZJ
J Biomed Mater Res A; 2020 Jan; 108(1):30-38. PubMed ID: 31433913
[TBL] [Abstract][Full Text] [Related]
6. Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
[TBL] [Abstract][Full Text] [Related]
7. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
8. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Zeyada MS; Abdel-Rahman N; El-Karef A; Yahia S; El-Sherbiny IM; Eissa LA
Life Sci; 2020 Nov; 261():118458. PubMed ID: 32961231
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
10. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
11. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
12. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
[TBL] [Abstract][Full Text] [Related]
14. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
15. Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug.
Ren J; Wang B; Wu Q; Wang G
Biomed Pharmacother; 2022 Nov; 155():113789. PubMed ID: 36271567
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
17. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway.
Zhu Y; Zuo W; Chen L; Bian S; Jing J; Gan C; Wu X; Liu H; Su X; Hu W; Guo Y; Wang Y; Ye T
Biochem Pharmacol; 2019 Nov; 169():113610. PubMed ID: 31465777
[TBL] [Abstract][Full Text] [Related]
19. Niclosamide: Beyond an antihelminthic drug.
Chen W; Mook RA; Premont RT; Wang J
Cell Signal; 2018 Jan; 41():89-96. PubMed ID: 28389414
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line.
Cheng B; Morales LD; Zhang Y; Mito S; Tsin A
PLoS One; 2017; 12(9):e0184324. PubMed ID: 28877265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
